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Abstract
Background: The rat hybridoma cell line YB2/0 appears a good candidate for the large-scale production of low
fucose recombinant mAbs due to its lower expression of fut8 gene than other commonly used rodent cell lines.
However, important variations of the fucose content of recombinant mAbs are observed in production culture
conditions. To improve our knowledge on the YB2/0 fucosylation capacity, we have cloned and characterized the
rat fut8 gene.
Results: The cDNAs encoding the rat a1,6-fucosyltransferase (FucT VIII) were cloned from YB2/0 cells by
polymerase chain reaction-based and 5’ RNA-Ligase-Mediated RACE methods. The cDNAs contain an open reading
frame of 1728 bp encoding a 575 amino acid sequence showing 94% and 88% identity to human and pig
orthologs, respectively. The recombinant protein expressed in COS-7 cells exhibits a a1,6-fucosyltransferase activity
toward human asialo-agalacto-apotransferrin. The rat fut8 gene is located on chromosome 6 q and spans over 140
kbp. It contains 9 coding exons and four 5’-untranslated exons. FISH analysis shows a heterogeneous copy number
of fut8 in YB2/0 nuclei with 2.8 ± 1.4 mean copy number. The YB2/0 fut8 gene is expressed as two main transcripts
that differ in the first untranslated exon by the usage of distinct promoters and alternative splicing. Luciferase
assays allow defining the minimal promoting regions governing the initiation of the two transcripts, which are
differentially expressed in YB2/0 as shown by duplex Taqman QPCR analysis. Bioinformatics analysis of the minimal
promoter regions upstream exons E-2 and E-3, governing the transcription of T1 and T2 transcripts, respectively,
evidenced several consensus sequences for potential transcriptional repressors. Transient transfections of Rat2 cells
with transcription factor expression vectors allowed identifying KLF15 as a putative repressor of T1 transcript in
Rat2 cells.
Conclusion: Altogether, these data contribute to a better knowledge of fut8 expression in YB2/0 that will be useful
to better control the fucosylation of recombinant mAbs produced in these cells.
Background
Several independent studies have clearly shown that
effector functions of recombinant therapeutic IgG are
directly dependent on the glycosylation of the constant
region (Fc) [1-3]. Each heavy chain of IgG1 Fc fragment
contains a single N-glycosylation site substituted by a
biantennary complex glycan. The minimal core structure
is a heptasaccharide (GlcNAc2Man3GlcNAc2) potentially
substituted by galactose (Gal), bisecting N-acetylglucosa-
mine (GlcNAc), sialic acid (Neu5Ac) and/or fucose
(Fuc) residue a1,6-linked to the first GlcNAc attached
to Asn297 of IgG heavy chains [4].
IgG Fc oligosaccharides determine the overall confor-
mation of the Fc fragment [5] and modulate the capacity
of IgG to interact with FcgR [6]. Therefore, it is clearly
established that the Antibody-Dependent Cellular
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sylation of the Fc region of mAbs (for review [7]). The
specific role in ADCC of each monosaccharide substi-
tuting the core structure has been studied in details,
showing the key role of the core fucose in cellular toxi-
city [8-10]. Low fucose IgG1 (10-20%) exhibit a higher
ADCC activity compared to highly fucosylated IgG
(80-90%) either in vitro [8] or in vivo [10].
The most widely used recombinant antibodies are pro-
duced by rodent mammalian cell lines with intrinsic fuco-
syltransferase activity (e.g., Chinese hamster ovary (CHO),
mouse myeloma and hybridoma cell lines). Therefore,
almost all licensed therapeutic antibodies developed to
date are heavily fucosylated [11,12], which results in a
non-optimized ADCC. Reducing the a1,6-fucose rate of
IgG Fc has been a challenge over the last few years to pro-
vide maximum efficiency to recombinant mAbs.
In mammals, the GDP-L-Fuc: N-acetyl-b-D-glucosa-
minide a1,6-fucosyltransferase (a1,6-FucT) is the only
enzyme able to catalyze the transfer of a Fuc residue in
a1,6-linkage to the first GlcNAc residue of N-glycan
chains [13]. GDP-fucose, the unique donor substrate of
fucosyltransferases, is synthesized in the cytoplasm from
GDP-mannose, via three enzymatic reactions carried out
by two proteins: GDP-mannose 4,6-dehydratase (GMD)
and GDP-4-keto-6-deoxymannose 3,5-epimerase,
4-reductase (FX) [14,15]. The GDP-fucose is then
transported into the lumen of the Golgi apparatus by a
GDP-fucose transporter (GFT) located at the Golgi mem-
brane [16], where it serves as a substrate in the synthesis
of fucosylated glycoconjugates [15,17,18]. a1,6-FucT is
encoded by the fut8 gene and different strategies target-
ing fut8 or other fucose-related genes have been devel-
oped to reduce the fucosylation capacity of recombinant
mAb producing cells. The fut8 gene [19], the GMD
gene [20], or both [21] have been knockdown in CHO
cells, generating completely non-fucosylated recombi-
nant mAbs. Fut8 siRNA was also used for engineering
CHO cells to upgrade effector function of produced
antibodies [22] and recently, short-hairpin-RNA has
been developed for the silencing of fut8 in CHO, result-
ing in an enhanced antibody immune effector function
[23]. Glycosylation inhibitors were also proposed to
enhance cellular toxicity of recombinant IgG [24] and
lectin-affinity chromatography techniques have been
applied to enrich in non-fucosylated species the
produced recombinant mAbs [25].
Alternative cell lines have been tested for the reduc-
tion of core fucose on recombinant mAbs. The Lec13
mutant CHO cell line, partially deficient in GMD [26]
was used to produce human IgG1 that were deficient in
fucose [8]. As an alternative, the rat hybridoma cell line
YB2/0 was proposed as a good candidate for the large-
scale production of low fucose IgG [9]. Thus, this cell
line has a very good capacity of IgG biosynthesis and its
fucose transfer capacity is much lower than the other
rodent cell lines commonly used [27]. However, impor-
tant variations of the fucose content has been observed
for the producing clones in production culture condi-
tions [28], indicating that a better knowledge of the
capacity of the YB2/0 fucosylation machinery is required
for optimizing the fucosylation of recombinant mAbs at
the production level. Thus, we have analyzed the fucosy-
lation capacity of YB2/0 and we report here the molecu-
lar cloning of the rat fut8 cDNA, the fut8 gene
organization including 5’-untranslated exons and tran-
scription start-sites, the number of fut8 copies in YB2/0
nuclear genome and the analysis of two promoter
regions (P1 and P2) governing fut8 transcription in
these cells. In particular, we identified several potential
repressor binding sequences in both minimal promoters
and showed that KLF15 can repress the activity of P1
promoter region.
Methods
Cell culture
The rat cell line YB2/0 was obtained from American
Type Culture Collection (Manassas, VA, http://www.atcc.
org; catalog n° CRL-1662) and grown in EMS™ medium
(optimized and patented culture medium developed by
the Laboratoire Français du Fractionnement et des Bio-
technologies, Lille, France) supplemented with 5% heat
inactivated FCS (Invitrogen, Carlsbad, CA, USA) at 37°C
under 5% CO2. The rat Rat2 cell line (ATCC n° CRL-
1764) and COS-7 (ATCC n° CRL-1651) were cultivated
in Dulbecco’s modified Eagle’sm e d i u m ,D M E M ,
(BioWittaker, Lonza, Brussels, Belgium) supplemented
with 10% heat-inactivated FCS and 2 mM of L-glutamine
(Lonza, Brussels, Belgium) at 37°C in 5% CO2.
Bio-informatics analysis
In silico analysis was performed with BLAST analysis of
rat genomic and expressed sequence tags (EST) divi-
sions of the NCBI databases http://www.ncbi.nlm.nih.
gov/sites/entrez. Multiples e q u e n c ea l i g n m e n t sw e r e
performed with the Clustal W program http://www.ebi.
ac.uk/Tools/clustalw2/index.html. Expasy site http://
www.expasy.ch was used for protein analysis. Analysis of
minimal promoter regions was performed with Matin-
spector 2.2 http://www.genomatix.de using TRANSFAC
matrices 4.0 [29] with “core similarity: 0.9” and
“matrices similarity: Optimized”. Filters corresponding
to myeloid and lymphoid cells were used to screen spe-
cific cells transcription factors.
RNA isolation and cDNA synthesis
YB2/0 cells were used as source of RNA. Total RNA
was extracted using the Nucleospin RNA II (Macherey-
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vided by the manufacturer. Total RNA (2 μg) was
reverse-transcribed using first strand cDNA synthesis kit
(Amersham Biosciences, Freiburg, Germany).
Molecular cloning of rat a1,6 fucosyltransferase cDNA
The a1,6-fucosyltransferase open reading frame was
amplified from 1 μL of YB2/0 cells cDNA with the pri-
m e rp a i r5 F 8 r 2 :5 ’-agtcgccacaggattacc-3’and 3F8r2: 5’-
atctgcttagccgagatg-3’ at 94°C for 2 min, followed by 30
cycles (94°C, for 30 sec; 50°C for 45 sec; 68°C for 2 min
10 sec) and an extension step of 10 min at 68°C. The
PCR product was cloned into the pCR II-Blunt TOPO
vector (Invitrogen, Carlsbad, CA, USA). The encoding
sequence was isolated by digestion of the vector using
HindIII and XbaI restriction sites. The purified fragment
was subcloned into pcDNA3.1 vector (Invitrogen, Carls-
bad, CA, USA) digested by HindIII and XbaI. The resul-
tant plasmid was designed pcDNA-Fut8. COS-7 cells
were transiently transfected with pcDNA-Fut8 or the
empty plasmid using lipofectamine (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer’s instruc-
tions. Cells were harvested 48 h after transfection.
Preparation of the asialo-agalacto apotransferrin acceptor
substrate
After dialysis against sodium acetate buffer (50 mM, pH
7.5), 5 mg of human apotransferrin (Sigma-Aldrich,
Lyon, France) were incubated with 120 mU of Arthro-
bacter ureafasciens neuraminidase (Sigma-Aldrich, Lyon,
France) and 50 mU of Escherichia Coli b-galactosidase
(Sigma-Aldrich, Lyon, France) at 37°C for 24 h in a final
volume of 10 mL. After 4 h of dialysis against water,
asialo-agalacto-apotransferrin was freeze-dried. The
absence of galactose and sialic acid residues was con-
trolled by GC-MS.
Fucosyltransferase assay
COS-7 cells, transiently transfected with pcDNA-Fut8 or
the empty plasmid, were harvested by scrapping in a 4
mM EDTA solution, pelleted by low-speed centrifuga-
tion and resuspended in lysis buffer (150 mM NaCl, 50
mM Tris-HCl, pH 7.5, 1% Triton X-100), containing a
cocktail of proteases and phosphatase inhibitors (Roche,
Basel, Switzerland). The protein concentration of protein
extracts was determined with the Micro BCA™Protein
Assay Reagent kit (Thermo Fisher Scientific Inc, Rock-
ford, IL, USA).
Enzyme assays were performed with 20 μLo fp r o t e i n
extract (140 μg/mL), 70 mM cacodylate buffer (pH 7.2)
10 mM L-fucose, 6 μMG D P - [
14C]-L-fucose (299 mCi/
mmol, Amersham Biosciences, Pantin, France), 10 mM
GDP-fucose and 100 μg asialo-agalacto human apotrans-
ferrin as acceptor substrate, in a final volume of 50 μL,
at 30°C for 4 h. The reaction was stopped with 150 μL
of RT water, precipitated with 1 mL of 5% phospho-
tungstic acid and processed for scintillation counting.
The transfer of [
14C]-fucose is expressed in cpm.
Amplification of 5’cDNA ends by RNA-Ligase-Mediated
RACE (RLM-RACE)
RLM-RACE [30] amplifications were performed using
the GeneRacer kit (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Initial
reverse transcription was performed with the oligo dT
primer using 5 μg of total RNA. After synthesis of the
first strand cDNA, PCR were performed with the Gen-
eRacer5’Primer from the kit and a gene-specific primer
3F8Race3 5’-cttcccgtagccgtcccctggtcaa-3’ at 94°C for 2
min, followed by 38 cycles (94°C, for 45 sec; 57°C for 45
sec; 68°C for 1 min 45 sec) and an extension step of 10
min at 68°C. Nested PCR were performed with the Gen-
eRacer5’Primer Nested provided in the kit and a gene-
specific primer 3F8Race4 5’-actcagccattcgcctcaagtcttc-3’,
using 2 μL of the first PCR amplification and the same
conditions as the first PCR. PCR amplifications were
performed with Taq AccuPrime (Invitrogen, Carlsbad,
CA, USA) according to the provider’s instructions.
Nested-PCR products were size separated by Agarose
gel electrophoresis, subcloned into pCR4-TOPO vector
(Invitrogen, Carlsbad, CA, USA) and sequenced by Gen-
oscreen (Lille, France).
Reverse transcription and quantitative PCR
The expression of the transcripts 1 and 2 was analyzed
by quantitative real-time PCR. 2 μgo ft o t a lR N Aw a s
reverse transcribed with poly-T oligonucleotide using
Affinity script QPCR cDNA Synthesis kit (Agilent tech-
nologies, Santa Clara, CA, USA) according to the proto-
col provided by the manufacturer. Parallel reactions
without SuperScript (RT controls) were performed to
assess the degree of contaminating genomic DNA.
Duplex Taqman™ QPCR and subsequent analysis were
performed using the Mx-4000 Quantitative System
(Stratagene, Amsterdam, the Nederlands). Primers and
probes were designed using Primer Express software
(Applied Biosystems, Carlsbad, CA, USA) (Table 1). The
probes were MGB Taqman™ probes synthesized by
Applied Biosystems. The Transcript 1 (T1) and Tran-
script 2 (T2) probes were FAM-labeled and the refer-
ence gene HPRT probe was VIC-labeled. PCR reactions
were performed with 12.5 μL of the Quantitect Multi-
plex PCR kit (Qiagen, Courtaboeuf, France), 0.4 μMo f
each primer, 0.2 μM of HPRT Taqman™ probe, 0.2 μM
of T1 or T2 Taqman™ probe and 2 μLo fc D N Ai na
final volume of 25 μL. After 95°C for 15 min, 40 PCR
cycles were performed as follows: 95°C for 1 min, 60°C
for 1 min. Assays for each transcript were performed in
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3 times. Relative amounts of mRNAs were based on
standard curves prepared by a serial dilution of control
YB2/0 cDNA.
FISH (Fluorescence In Situ Hybridization)
The YB2/0 cell line was grown in EMS™ medium supple-
mented with 5% heat inactivated FCS for 72 hours prior
cell fixation and in situ hybridization. Primary rat lym-
phocytes were isolated from rat blood following standard
procedures. The probes used for the FISH analysis were
designed and prepared as follow: fut8 and a non relevant
probe (NRP) for rat genome were designed by using
respectively 3 and 2 BACs. Bacteria were amplified in LB
Broth, and then BACs were purified on Anion Exchange
columns (Qiagen, Courtaboeuf, France) following the
manufacturer’s instructions. Probes labeling was then
performed using the ARES Alexa Fluor 488 Labeling kit
(Invitrogen, Carlsbad, CA, USA), while the purification
was done with the PureLink PCR Purification Kit (Invi-
trogen, Carlsbad, CA, USA). To avoid probes unspecific
binding to repetitive DNA sequences, samples were pre-
cipitated with 1 μg of Rat Hybloc competitor DNA
(Insight Biotechnology Limited, Wembley, UK).
The FISH assays were carried out in standard condi-
tions. Fluorescent DNA probes and samples were dena-
tured for 10 min at 73°C. The hybridizations were
performed overnight at 37°C in a humidified chamber.
The coverslides were then washed 3 times at 45°C with
50% formamide in SSC2X, one time in SSC2X before a
final wash in SSC2X, 0.1% NP-40. Finally, nuclei were
counterstained for 30 min at 4°C in darkness, with
DAPI III/mountain medium (Abbott-France, Rungis,
France) before observation under an epifluorescence
microscope (Olympus, BX61) using appropriated fluor-
escent filters.
Raw data of the FISH analysis were compared with
statistical methods by using SPSS 13.0 software. Data were
analyzed under the normality test Kolmogorov-Smirnov,
before applying non parametric Kruskal-Wallis and
U-Mann Whitney tests. Statistical differences between
samples were considered significant when p < 0.05.
Construction of reporter plasmids for luciferase assays
Genomic DNA of YB2/0 cells were prepared with
Nucleospin Extract II kit (Macherey Nagel, Düren,
Germany) following manufacturer’si n s t r u c t i o n s .T o
analyze the T1 transcript promoter region, the genomic
sequence located between the -1438 bp and -411 bp
upstream the ATG was amplified by PCR using the pri-
mer pair: FP1.8: 5’-cgtggcaagcttccctaacgcccccttacccg-3’
and FP1.7: 5’-ctccctggtacctccgtactcaataaacttccgcc-3’
introducing HindIII and KpnI restriction sites (under-
lined in the oligonucleotide sequences), respectively.
The PCR product was subcloned into pGL3-basic vector
(pGL3b, Promega, Madison, USA) upstream of the fire-
fly luciferase gene at HindIII/KpnI sites. The resulting
plasmid was designed pGL3(-1438/-411). This PCR frag-
ment was submitted to 5’ and 3’ deletions using natural
restriction enzyme sites and cloned in pGL3b to gener-
ate various vectors (Table 2).
To analyze the T2 transcript promoter region, the
genomic region of 1,000 bp upstream exon E-3 was
amplified from YB2/0 cells genomic DNA using primers
FKO11 5’-ccgggctagcacattccacccctgactcctaa-3’ and
FKO12 5’-ccggctcgaggtttcctacccgctcgcactcg-3’ creating
NheI and XhoI restriction sites (underlined in the oligo-
nucleotide sequences), respectively. The amplified frag-
ment was subcloned into pGL3b. The plasmid was
called pGL3(-1399/-404). Following the same strategy,
nested PCR fragments were subcloned into pGL3b
upstream the firefly luciferase gene at NheI/XhoI sites
(Table 3). The different constructions were sequenced
to ensure the absence of mutations.
Transient transfections and luciferase assay
Rat2 cells were transiently transfected using lipofecta-
mine (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions, using 1 μg/mL of pGL3b
construction and 10 ng/mL of control Renilla plasmid
in OptiMEM medium (Invitrogen, Carlsbad, CA, USA).
After 6 h, the medium was changed for fresh cell
Table 1 Probes and primer sequences used for TaqMan™
quantitative PCR experiments
Target Forward Primer
Reverse Primer
Probe
Transcript T1 5’-cgcgggctgctgttc-3’
5’-ataataatggaaaggactt
gatcttgg-3’
5’-ccctggtggcgtt-3’
Transcript T2 5’-ccgcttagctcgccctcta-3’
5’-aggactagatcttggatgaaaacg-3’
5’-agtccttcggcccacg-3’
HPRT 5’-tgtacttggcttttccactttcg-3’
5’-tgcccttgactataatgagcacttc-3’
5’-atgacacaaacatg
attca-3’
Table 2 Reporter plasmids for T1 transcript luciferase
assays
Digestion Position of the fragment Vector name
ApaI, HindIII -1205/-411 pGL3(-1205/-411)
BseRI, HindIII -1004/-411 pGL3(-1004/-411)
NheI, HindIII -892/-411 pGL3(-892/-411)
MseI, HindIII -598/-411 pGL3(-598/-411)
KpnI, PvuI -1438/-451 pGL3(-1438/-451)
KpnI, PvuI -1205/-451 pGL3(-1205/-451)
NheI, PvuI -892/-451 pGL3(-892/-451)
KpnI, MseI -1438/-598 pGL3(-1438/-598)
KpnI, MseI -1205/-598 pGL3(-1205/-598)
NheI, MseI -892/-598 pGL3(-892/-598)
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CO2. Cells were then washed one time with PBS, lysed
in 150 μL of Passive Lysis Buffer (PLB, Dual Luciferase
Reporter Assay System, Promega, Madison, USA) and
20 μL of lysate were used for luciferase Reporter Assay
System. Luminescence was measured with the Centro
luminometer (Berthold Technologies, Bad Wildbad,
Germany).
The YB2/0 cells were transiently transfected with Cell
line Nucleofector
® kitV (Amaxa Lonza, Verviers, Bel-
gium) according to manufacturer’s instructions. 2 × 10
6
cell pellets were resuspended in 100 μLo fN u c l e o f e c -
tor
® kitV solution. The cell suspensions were mixed
with 2 μg of pGL3b construction and 20 ng of control
Renilla plasmid. The mixtures were transferred into an
Amaxa cuvette and submitted to nucleofection using the
T-020 program. Cells were plated on 6-well plates with
2 mL of culture medium and incubated for 24 h at 37°C
in 5% CO2. Cells were then centrifuged 5 min at 1,200
rpm, washed one time with PBS and processed for luci-
ferase reporter assay as described for Rat2.
The pcDNA3.1 expression vector encoding the human
KLF15 transcription factor (pcDNA-hKLF15) was kindly
provided by Dr. Otteson, College of Optometry, Univer-
sity of Houston, USA. For transfection of Rat2 cells, 25
to 500 ng/mL of pcDNA-hKLF15 vector were added to
the lipofection mix.
Nuclear and cytoplasm protein extraction, Western
blotting analysis
48 hours after transfection with KLF15 vector, Rat2 cells
were lysed on ice in a hypotonic buffer (Hepes 10 mM,
MgCl2 1,5 mM, KCl 10 mM, pH 7.9) supplemented
with 0.125% NP-40 and protease cocktail inhibitors
(Roche, Meylan, France). The lysate was centrifuged for
5 min at 10,000 g and the cytosolic fraction was
obtained in the supernatant. The pellet corresponding
to the nuclear fraction was lysed with hypertonic buffer
(Hepes 20 mM, MgCl2 1.5 mM, EDTA 0.2 mM, NaCl
0.5 M, glycerol 25%, pH 7.9) supplemented with pro-
tease cocktail inhibitors on ice during two hours. The
protein concentration of both fractions was determined
with the Micro BCA™Protein Assay Reagent kit (Pierce,
R o c k f o r d ,I L ,U S A ) .2 0μg of total proteins were boiled
for 10 min in reducing Laemmli sample buffer and
resolved by SDS-PAGE on 8% mini-gels (Bio-Rad, Rich-
mond, USA). After transfer onto a nitrocellulose mem-
brane (80 mA overnight), blocking was performed using
TBS (Tris Buffer Saline) containing 0.05% Tween 20 and
5% (w/v) non-fat dried milk for one hour at room tem-
perature (RT). Incubations with 2.5 μg/mL anti-KLF15
mAb (AbCam, Cambridge, UK) or 0.04 μg/mL anti-
actin mAb (Santa Cruz Biotechnology Inc., Europe)
were performed one hour at RT in TBS, 0.05% Tween
20 and 5% (w/v) non-fat dried milk. After washing,
membranes were incubated for 1 h at RT with 1/15,000
dilution in TBS, 0.05% Tween 20 and 5% (w/v) non-fat
dried milk of horseradish peroxidase conjugated anti-
goat IgG for KLF15 or anti-rabbit IgG for actin. Mem-
branes were finally washed three times for 10 min in
TBS, 0.05% Tween 20 and detection was achieved using
enhanced chemiluminescence (ECL+
® advanceWestern
blotting detection reagents, Amersham Biosciences, Lit-
tle Chalfont, Buks, U.K.).
Electrophoretic mobility shift assays (EMSA)
Biotin 5’ end-labeled (-892/-451) promoter DNA probe
was obtained by PCR from pGL3(-892/-451) plasmid
using biotin 5’ end-labeled primers (forward P1 min 5’-
gctagcgccggcccgaggct-3’, reverse P1 min 5’-
cgatcggcgccgtcccccgt-3’). Rat2 cells nuclear extract was
prepared as previously described. EMSA was performed
with a Lightshift
® Chemiluminescent EMSA kit
(Thermo Scientific, Waltham, USA) as follows. Nuclear
extract (3 μg protein) was incubated for 20 min at room
temperature in 1 × binding buffer, 2.5% glycerol, 5 mM
Table 3 Primers used for the construction of plasmids for T2 transcript luciferase assays
Forward primer Reverse primer Vector name
FKO13-NheI
5’-ccgggctagcgtttatttccaacagagtacacgactc-3’
FKO12-XhoI
5’-ccggctcgaggtttcctacccgctcgcactcg-3’
pGL3(-1233/-404)
FKO15-NheI
5’-ccgggctagccaggtgaggagctgctgaaggcacagac-3’
FKO12-XhoI
5’-ccggctcgaggtttcctacccgctcgcactcg-3’
pGL3(-998/-404)
FKO17-NheI
5’-ccgggctagcgtcttgagggcagcttttctactcagc-3’
FKO12-XhoI
5’-ccggctcgaggtttcctacccgctcgcactcg-3’
pGL3(-720/-404)
FKO11-NheI
5’-ccgggctagcacattccacccctgactcctaagaccaac-3’
FKO14-XhoI
5’-ccggctcgaggtcgccggccgggtgccaccggggccaatc-3’
pGL3(-1399/-537)
FKO13-NheI
5’-ccgggctagcgtttatttccaacagagtacacgactc-3’
FKO14-XhoI
5’-ccggctcgaggtcgccggccgggtgccaccggggccaatc-3’
pGL3(-1233/-537)
FKO15-NheI
5’-ccgggctagccaggtgaggagctgctgaaggcacagac-3’
FKO14-XhoI
5’-ccggctcgaggtcgccggccgggtgccaccggggccaatc-3’
pGL3(-998/-537)
FKO17-NheI
5’-ccgggctagcgtcttgagggcagcttttctactcagc-3’
FKO14-XhoI
5’-ccggctcgaggtcgccggccgggtgccaccggggccaatc-3’
pGL3(-720/-537)
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of biotin-labeled probe, in a final volume of 20 μL.
4 pmol of unlabeled (-892/-451) promoter DNA were
added to the binding reaction mixture for competition
studies. For supershift analysis, 1 μg of anti-KLF15 mAb
(AbCam, Cambridge, UK) was pre-incubated with
nuclear extract for 1 h at 4°C prior to the binding
reaction. Reaction products were separated by electro-
phoresis in a 4% polyacrylamide gel (29:1, acrylamide/N,
N’-methylene bisacrylmamide) in 0.5 × TBE. The
protein-DNA complexes were then transferred onto a
positively charged nylon membrane (Hybond-N+, Amer-
sham Pharmacia Biotech, Uppsala, Sweden) and detected
by chemiluminescence.
Results
Isolation and characterization of the rat a1,6
fucosyltransferase cDNA
In order to clone the rat fut8 cDNA, the putative rat
mRNA sequence of 1728 pb (NM_001002289.1) pro-
vided by the NCBI genome annotation division http://
www.ncbi.nlm.nih.gov/sites/entrez was used as a probe
for BLAST analysis of rat genomic and EST divisions of
NCBI databases. The coding sequence of rat a1,6 fuco-
syltransferase was localized on chromosome 6, divided
into nine exons and spanning over 140 kb (Figure 1A).
Homologous EST sequences obtained were conceptually
translated and partially overlapping sequences were
assembled to build a larger open reading frame (ORF)
(Figure 1B). Three ESTs CB548120.1, CB 730213.1 and
CB730572.1 correspond to the 5’-region of the fut8
gene, and the sequences FM069692.1, DV727207.1 and
CB742993.1 correspond to the 3’-region. These
sequences were used to generate oligonucleotide primers
located in the 5’-a n d3 ’-untranslated regions for PCR
cloning. A unique 1942 pb PCR fragment was amplified
from YB2/0 cells cDNA library, cloned into the pCR II-
Blunt TOPO vector and entirely sequenced.
The amplified sequence contains an ORF of 1725 bp,
showing 4 nucleotide changes (at +340 (a/c), +418 (t/c),
+891 (t/c) and 1313 (c/t) from ATG) compared to the
putative rat fut8 ORF sequence (NM_001002289.1),
which were also found, at least for two of them, in EST
sequences of the NCBI databases (125463675/
102469807, 1660740078/8735204) and reflect a silent
allelic polymorphism in rat fut8 gene without change
in the amino-acid sequence of the polypeptide.
The nucleotide and deduced amino acid sequences of
the full-length cDNA obtained are shown in Figure 2.
The position of the initiation codon was estimated
according to the Kozak consensus sequence [31]. Hydro-
pathy analysis of the polypeptide indicated the presence of
a hydrophobic sequence of 19 amino acids in the NH2-
terminal region, corresponding to the transmembrane
domain characteristic of type II Golgi glycosyltrans-
ferases. The predicted protein consisted of 575 amino
acids, containing the three specific motifs of a1,6-
fucosyltranferase in the catalytic domain (Figure 2). Com-
parison of the amino acid sequence with those of the
human and pig orthologs, shows 94% and 88% identity,
respectively.
In order to conclusively confirm that the YB2/0
cloned fut8 cDNA encodes an active a1,6-fucosyltrans-
ferase, the cDNA was inserted in pcDNA3.1 expression
vector. The construction was transiently transfected into
COS-7 cells. 72 h after transfection, the a1,6-fucosyl-
transferase activity was measured in cell extracts using
asialo-agalacto apotransferrin as acceptor substrate for
in vitro assays. The a1,6-fucosyltransferase activity was
4 times higher (2135 +/- 318 cpm) in pcDNA-Fut8
transfected COS-7 cell extracts than in the control cells
(500 +/- 200 cpm), confirming that the cloned cDNA
encodes an active enzyme.
Fluorescence In Situ Hybridization
Copy number of fut8 gene was counted on at least 50
interphase nuclei of YB2/0 cell line and appropriated
controls. Results are summarized as percentage and
mean copy number in Table 4 and representative pic-
tures of the different samples are shown in Figure 3. It
appears that the rat myeloma cell line YB2/0 has a
mean copy number of fut8 g e n eo f2 . 8±1 . 4w h e r e a s
the rat primary lymphocyte has only 2.3 ± 0.8 of the
same gene and the negative control with the NRP shows
no hybridization. These differences are statistically
significant with p < 0.05.
Identification of rat fut8 transcription start sites
To determine the transcriptional start sites (TSS) of rat
fut8 gene, the mRNA 5’-ends were amplified by RLM-
RACE. To ascertain to only amplify full-length tran-
scripts, we first selected full-length capped mRNA from
total RNA extracted from YB2/0 cells. For that purpose,
total RNA was first treated with calf intestine alkaline
phosphatase for total dephosphorylation of uncapped
RNAs, thereafter the full-length mRNA was uncapped
with tobacco acid pyrophosphatase. The geneRacer RNA
oligonucleotide was then ligated to the 5’-phosphate of
the uncapped mRNA using T4 RNA ligase. Reverse
transcription was performed with the GeneRacer oli-
godT primer, followed by a first PCR using the forward
GeneRacer5’Primer provided and the reverse gene-speci-
fic primer 3F8Race3 located at the 5’-end of exon E2.
Nested PCR was performed with the forward GeneRa-
cer5’Primer Nested provided and the reverse gene-speci-
fic primer 3F8Race4 located into the first coding exon
E1. As shown in Figure 4A, which is representative of at
least three independent amplifications, four bands from
Teylaert et al. BMC Biotechnology 2011, 11:1
http://www.biomedcentral.com/1472-6750/11/1
Page 6 of 18250 to 750 bp were obtained. The PCR products were
subcloned, sequenced and BLAST-aligned http://www.
ncbi.nlm.nih.gov/BLAST/ against the rat genome. As
expected, the amplified products were assigned to rat
fut8 transcripts (NW_047761.1, NW_047771.1) excepted
for the 450 bp band, which was not specific. Three dif-
ferent 5’-ends of fut8 mRNA were identified, testifying
the existence of three transcript isoforms. The T1 tran-
script [EMBL: FN668936] corresponding to the 600 bp
amplified fragment, is extended by 508 bp from the
ATG and composed of 4 exons named E-2, E-1, E0 and
E1 as shown in Figure 4B. Twenty different clones from
three independent RLM-RACE were sequenced, defining
3 TSS for T1, at -508, -500 and -447 bp from the ATG
(Figure 4B). The T2 transcript [EMBL: FN668937], cor-
responding to the 750 bp amplified product, is extended
by about 537 bp and composed, as well, of the exons
E-1, E0 and E1 but the exon E-2 is substituted by exon
E-3. The sequencing of 28 clones allowed the identifica-
tion of six TSS at position -537, -505, -498, -496, -473
a n d- 4 6 9b pf r o mt h eA T G( F i g u r e4 B ) .F i n a l l y ,t h eT 3
transcript [EMBL: FN668938] was the smallest one and
corresponded to the 250 bp product. The T3 transcript
5’-untranslated region was only composed of the 3’-end
of exon E1, with 5 TSS at position -222, -216, -171,
-129 and -46 from the ATG (Figure 4B). A schematic
representation of the 5’-untranslated region of fut8 gene
and of the three transcript isoforms identified by RLM-
RACEis shown in Figure 5. Similar results were obtained
for Rat2 cells and rat liver RNA preparations, excepted
for T3 transcript, the presence of which was not con-
firmed in both cases.
Quantification of transcripts in cultured cells by duplex
Taqman™ QPCR
The relative expression of fut8 specific transcripts was
determined by duplex Taqman™ QPCR using HPRT as a
normalizing gene. For T1 transcript, a forward primer
hybridizing within E-2 and a reverse primer that hybri-
dizes within the exon E-1/E-2 junction of fut8 cDNA
sequence were designed (Table 1). For the T2 transcript,
the primers pair was designed hybridizing within E-3
sequence for the forward primer and in the exon E-1
for the reverse primer. Taqman™ probes were designed
within exon E-1 and E-3, respectively. For HPRT,p r i -
mers and probe were designed to hybridize within exon
7/exon 8 sequences of the coding region (Table 1). The
relative expression of specific transcripts was determined
for YB2/0 and Rat2 cell lines. As shown in Figure 6, the
expression of T2 transcript was 1.6-fold higher than the
expression of T1. This pattern of expression was similar
in both cell lines (Figure 6).
The direct quantification of T3 transcript expression
was not possible because the totality of the 5’-UTR
sequence is common to the sequences of the T1 and T2
transcripts. Moreover, the quantification of the total tran-
scripts of fut8 using primers designed in E-1 and E0
exons didn’t allow determining the expression level of
T3. Nevertheless, the T3 transcript appeared to be weakly
expressed in both cell lines compared to T1 and T2.
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Figure 1 Genomic organization of rat fut8 gene. (A) The rat fut8 gene ORF is located on chromosome 6, and contains 9 exons (labeled E1-
E9), spanning 140 kbp. (B) Schematic representation of rat fut8 gene mRNA. The grey boxes represent the open reading frame and the open
boxes the 5’- and 3’-unttranslated regions, respectively. The black lines represent the rat EST identified in the public databases.
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To determine the minimal promoter region of the T1
transcript, the 1 kb genomic sequence between E-3 and
E-2 was subcloned in the pGL3b upstream the luciferase
gene and named pGL3(-1438/-411). This plasmid and
the 5’-o r3 ’-deleted constructions pGL3(-1438/-598),
pGL3(-1438/-451), pGL3(-598/-411), pGL3(-892/-411),
pGL3(-892/-451), pGL3(-892/-598), pGL3(-1004/-411)
and pGL3(-1205/-411), were transfected into YB2/0 and
Rat2 cells for luciferase assays. Unfortunately, the
-130                                           a acc tgt ttg aag cat cat gtg -109
-108 tta aaa caa cag aaa cct gtt ttc ttg tgt ggc taa cta gaa cca gag cac aat  -55
-54  gtt tcc agt tct ttg agc tcc agg aag ata gag gac aga gtt gaa act ctg aaa   -1
1    atg cgg gca tgg act ggt tcc tgg cgt tgg att atg ctc att ctt ttt gcc tgg   54
      M   R   A   W   T   G   S   W   R   W   I   M   L   I   L   F   A   W.    
55   ggg acc ttg ttg ttt tat ata ggt ggt cat ttg gtt cga gat aat gac cac cct  108
      G   T   L   L   F   Y   I   G   G   H   L   V   R   D   N   D   H   P  
109  gat cac tct agc aga gaa ctc tcc aag att ctt gca aag ctt gaa cgc tta aaa  162
      D   H   S   S   R   E   L   S   K   I   L   A   K   L   E   R   L   K  
163  caa caa aat gaa gac ttg agg cga atg gct gag tct cta cga ata cca gaa ggc  216
      Q   Q   N   E   D   L   R   R   M   A   E   S   L   R   I   P   E   G 
217  ccc att gac cag ggg acg gct acg gga aga gtc cgt gtt tta gaa gaa cag ctt  270
      P   I   D   Q   G   T   A   T   G   R   V   R   V   L   E   E   Q   L  
271  gtt aag gcc aaa gaa cag att gaa aat tac aag aaa caa gcc aga aat ggt ctg  324
      V   K   A   K   E   Q   I   E   N   Y   K   K   Q   A   R   N   G   L 
325  ggg aag gat cat gaa atc tta agg agg agg att gaa aat gga gct aaa gag ctc  378
      G   K   D   H   E   I   L   R   R   R   I   E   N   G   A   K   E   L  
379  tgg ttt ttt cta caa agt gaa ctg aag aaa tta aag cat tta gaa gga aat gaa  432
      W   F   F   L   Q   S   E   L   K   K   L   K   H   L   E   G   N   E 
433  ctc caa aga cat gca gat gaa att ctt ttg gat tta gga cac cat gaa agg tct  486
      L   Q   R   H   A   D   E   I   L   L   D   L   G   H   H   E   R   S 
487  atc atg acg gat cta tac tac ctc agt caa aca gat gga gca ggg gat tgg cgt  540
      I   M   T   D   L   Y   Y   L   S   Q   T   D   G   A   G   D   W   R 
541  gaa aaa gag gcc aaa gat ctg aca gag ctg gtc cag cgg aga ata act tat ctc  594
      E   K   E   A   K   D   L   T   E   L   V   Q   R   R   I   T   Y   L 
595  cag aat ccc aag gac tgc agc aaa gcc agg aag ctg gtg tgt aac atc aat aag  648
      Q   N   P   K   D   C   S   K   A   R   K   L   V   C   N   I   N   K 
649  ggc tgt ggc tat ggt tgc caa ctc cat cac gtg gtc tac tgt ttc atg att gct  702
      G   C   G   Y   G   C   Q   L   H   H   V   V   Y   C   F   M   I   A 
703  tat ggc acc cag cga aca ctc atc ttg gaa tct cag aat tgg cgc tat gct act  756
      Y   G   T   Q   R   T   L   I   L   E   S   Q   N   W   R   Y   A   T 
757  ggt gga tgg gag act gtg ttt aga cct gta agt gag aca tgc aca gac aga tct  810
      G   G   W   E   T   V   F   R   P   V   S   E   T   C   T   D   R   S  
811  ggc ctc tcc act gga cac tgg tca ggt gaa gtg aat gac aaa aat att caa gtg  864
      G   L   S   T   G   H   W   S   G   E   V   N   D   K   N   I   Q   V 
865  gtg gag ctc ccc att gta gac agc ctt cat cct cgg cct cct tac tta cca ctg  918
      V   E   L   P   I   V   D   S   L   H   P   R   P   P   Y   L   P   L 
919  gct gtt cca gaa gac ctt gca gat cga ctc gta aga gtc cat ggt gat cct gca  972
      A   V   P   E   D   L   A   D   R   L   V   R   V   H   G   D   P   A 
973  gtg tgg tgg gtg tcc cag ttc gtc aaa tat ttg att cgt cca caa cct tgg cta 1026
      V   W   W   V   S   Q   F   V   K   Y   L   I   R   P   Q   P   W   L 
1027 gaa aag gaa ata gaa gaa gcc acc aag aag ctt ggc ttc aaa cat cca gtc att 1080
      E   K   E   I   E   E   A   T   K   K   L   G   F   K   H   P   V   I  
1081 gga gtc cat gtc aga cgc aca gac aaa gtg gga aca gag gca gcc ttc cat ccc 1134
      G   V   H   V   R   R   T   D   K   V   G   T   E   A   A   F   H   P 
1135 atc gaa gag tac atg gta cat gtt gaa gaa cat ttt cag ctt ctc gca cgc aga 1188
      I   E   E   Y   M   V   H   V   E   E   H   F   Q   L   L   A   R   R 
1188 atg caa gtg gat aaa aaa aga gta tat ctg gct acc gat gac cct gct ttg tta 1242
      M   Q   V   D   K   K   R   V   Y   L   A   T   D   D   P   A   L   L  
1243 aag gag gca aag aca aag tac tcc aat tat gaa ttt att agt gat aac tct att 1296
      K   E   A   K   T   K   Y   S   N   Y   E   F   I   S   D   N   S   I 
1297 tct tgg tca gct gga cta cac aat cgg tac aca gaa aat tca ctt cgg ggc gtg 1350
      S   W   S   A   G   L   H   N   R   Y   T   E   N   S   L   R   G   V 
1351 atc ctg gat ata cac ttt ctc tct cag gct gac ttc cta gtg tgt act ttt tca 1404
      I   L   D   I   H   F   L   S   Q   A   D   F   L   V   C   T   F   S 
1405 tcc cag gtc tgt cgg gtt gct tat gaa atc atg caa acc ctg cat cct gat gcc 1458
      S   Q   V   C   R   V   A   Y   E   I   M   Q   T   L   H   P   D   A 
1459 tct gca aac ttc cac tct tta gat gac atc tac tat ttt gga ggc caa aat gcc 1512
      S   A   N   F   H   S   L   D   D   I   Y   Y   F   G   G   Q   N   A 
1513 cac aac cag att gcc gtt tat cct cac aaa cct cga act gat gag gaa att cca 1566
      H   N   Q   I   A   V   Y   P   H   K   P   R   T   D   E   E   I   P 
1567 atg gaa cct gga gat atc att ggt gtg gct gga aac cat tgg gat ggt tat tct 1620
      M   E   P   G   D   I   I   G   V   A   G   N   H   W   D   G   Y   S 
1621 aaa ggt gtc aac aga aaa ctt gga aaa aca ggc tta tat ccc tcc tac aaa gtc 1674
      K   G   V   N   R   K   L   G   K   T   G   L   Y   P   S   Y   K   V 
1675 cga gag aag ata gaa aca gtc aag tat ccc aca tat cct gaa gct gaa aaa tag 1728
      R   E   K   I   E   T   V   K   Y   P   T   Y   P   E   A   E   K   - 
1729 aga taa agt aga aga gat taa cca cag aac tca gtt cag ac                  1769
Figure 2 Rat fut8 cDNA sequence. Numbering of the cDNA begins with the initiation codon. The amino acid sequence is shown in single-
letter code. The putative 19 amino acid N-terminal transmembrane domain is boxed. The three a1,6-fucosyltransferase specific motifs (motifs I, II
& III) are underlined. The open boxes mark the position of differences with the provisional sequence.
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Page 8 of 18luminescence intensity measured in YB2/0 for these dif-
ferent constructions was too weak to allow determining
the promoter activity of this region in this cell line. The
results obtained for Rat2 are presented in Figure 7, and
show a 13-fold increase of luciferase activity for the full
length plasmid pGL3(-1438/-411) compared to pGL3b,
whereas the luciferase activity for pGL3(-1205/-411) and
pGL3(-1438/-451) constructs shows a 38- and 30-fold
increased activity, respectively. In parallel, luciferase
activity for the pGL3(-892/-598) and pGL3(-598/-411)
plasmids show only a 3- and 4-fold increased activity
compared to pGL3b. These data suggest the existence of
a minimal promoter region [EMBL: FN668939] (named
P1) within the sequence -892/-451, including positive
and negative regulation regions in -892/-598 and 598/-
451, respectively. In addition, the -1205/-1004 and
-451/-411 sequences include positive regulation regions,
whereas -1104/-892 sequence includes negative regula-
tion regions.
We also analyzed the 1 kb region located upstream
the E-3 exon with or without E-3 sequence to determine
the minimal promoter region controlling the transcrip-
tion of T2 transcript. The full length region with the
E-3 region was PCR amplified and subcloned in the
pGL3b upstream the luciferase gene and named pGL3
(-1399/-404). This plasmid, or 5’-o r3 ’-deleted construc-
tions were transiently transfected in Rat2 cells. All the
constructions increase the luciferase activity compared
to pGL3b. The results presented in Figure 8 show a
7 -t o1 1 - f o l di n c r e a s eo fl u c i f e r a s ea c t i v i t yf o rt h ec o n -
structions without the E-3 exon, whereas the luciferase
activity for constructs with E-3 exon shows a 28- and
36-fold increased activity. No significant differences in
luciferase activity were observed between the pGL3
(-1399/-537), pGL3(-998/-537) and pGL3(-720/-537)
constructions. These results suggest the existence of a
minimal promoter region [EMBL: FN668940] (named
P2) within the sequence -720/-537 upstream the ATG
and a positive regulation region in the exon E-3.
Bioinformatics analysis of P1 and P2 minimal promoter
regions
The putative minimal promoter regions upstream exons
E-2 and E-3 were analyzed with Matinspector 2.2 http://
www.genomatix.de using TRANSAC matrices 4.0 [29].
Lymphoid and myeloid cell-specific filters were applied
to sort the identified transcription factors consensus
sequences and core similarity was fixed at 95%. A parti-
cular attention was put on consensus sequences for
transcription factors with repressor activity, potentially
usable for the control of fucosylation in YB2/0. Results
of these bioinformatics analysis are shown in Figure 9.
In both cases, the analyses did not reveal any canonical
TATA or CAAT boxes, but several putative binding
sites for general transcription factors and for transcrip-
tion factors with repressor activity. For the P1 minimal
promoter region (-892/-451) controlling the transcrip-
tion of T1 transcript, consensus sequences for the puta-
tive repressors MZF1 (Myeloid Zinc Finger 1), PAX5
(Paired Box 5), KLF15 (Krüppel-like Factor 15), IRF3
(Interferon Regulatory Factor 3) and PRDM1 (Positive
Regulatory Domain containing 1) were identified
(Figure 9). For the P2 minimal promoter region, we
Table 4 Number of copies of fut8 gene in YB2/0
interphase nuclei
Number of copies
(% of cells)
Sample Type Probe 0 1 2 3 4 or
more
Mean ±
SD
YB2/0 Sample Rat
fut8
6.5 ND
b 8 60 25.5 2.8 ± 1.4
PRL
a Positive
control
Rat
fut8
ND 10 64 13 13 2.3 ± 0.8
YB2/0 Negative
control
NRP
c 100 ND ND ND ND
The number of copies of fut8 gene observed by FISH is expressed as a
percentage of cells.
a: primary rat lymphocyte.
b: not detected.
c: non relevant probe.

Figure 3 Fut8 copy number in interphase nuclei of YB2/0. Picture A shows nucleus hybridized with a non relevant probe. Pictures B, C and
D show YB2/0 nuclei with 2, 3 and 5 copies of fut8, respectively.
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Page 9 of 18identified potential repressor binding sites for HELT
(Hey like transcriptional repressor), CDP (CCAAT dis-
placement protein), MEL1 (MDS1/EVI1-like gene 1),
NKX3.1 (androgen-regulated homeobox protein), IKRS
(Ikaros) and the zinc-finger transcription factor Gfi-1.
Effect of KLF15 over-expression on the P1 minimal
promoter activity
In order to determine the effect of the potential repres-
sor transcription factors on minimal promoter P1 activ-
ity, we co-transfected Rat2 cells with MZF1, PAX5,
KLF15, IRF3 or PRDM1 expression vectors and with
reporter vector pGL3(-892/-451) containing the minimal
promoter P1 sequence. 48 hours after transfection, luci-
ferase assays were performed and showed that only
KLF15 was able to reduce the minimal promoter activity
of T1 transcript by about 50%, at each concentration of
vector tested (Figure 10B and additional file 1). These
results were statistically significant (P < 0.0005) and sug-
gested that KLF15 had repressor activity. A similar
repressor effect of KLF15 was observed on the on pGL3
(-1438/-451) construct (data not shown). The over-
expression of KLF15 protein was checked by Western
Blot in nucleus and cytoplasm fractions of Rat2 cells. As
shown in Figure 10A, the anti-KLF15 mAb revealed two
bands at about 55 kDa, in agreement with the apparent
molecular weight of KLF15 protein in SDS-PAGE [32].
Endogenous KLF15 was mainly present in the cytosolic
fraction (see mock cells) and the amount of KLF15 pro-
tein increased in both in nucleus and cytoplasm frac-
tions with the concentration of transfected vector in a
dose-dependent manner. At the lowest concentration of
vector, KLF15 is mainly over-expressed in the nucleus
fraction and the repression of luciferase activity for
higher concentrations of vector doesn’t change in spite
of the increase of the protein in both fractions. These
data indicate that the smallest quantity of KLF15 that
accumulates in the nucleus is sufficient to observe a
maximal repressor effect.
Binding of nuclear proteins to P1 minimal promoter
sequence
To investigate the association between nuclear proteins
and the (-892/-451) P1 minimal promoter sequence,
EMSA assay was performed to determine whether Rat2
cells nuclear proteins could bind this sequence. As
shown in Figure 10C, a strong band was shifted (open
arrow) when the nuclear extract was incubated with the
biotinylated DNA fragment. The shifted band was signif-
icantly inhibited by a molar excess of unlabeled compe-
titor. In order to further determine if KLF15 binds to
 ϭϮ ϯϰ
ϮϱϬďƉ
ϲϬϬďƉ
ϳϱϬďƉ
dϭƚƌĂŶƐĐƌŝƉƚ
-508     agcacccc
-500 tcccactctcccggcgcggccagctgcagctgaaggcagcggctgtggcg
-450 acgggggacggcgccgatcgcctcgctcccgccgcgggctgctgttctgg
-400 ctgaggctgtctatggccctggtggcgttttcatccaagatcaagtcctt
-350 tccattattatttattaactgaacagattcagctaataatcttcaagacc
-300 cagatccaagcaataatacacttctctgcagtaccatgtggctttcctca
-250 gcaacctgagtctatgggaaggaagcatgtagagttcatgaagcacaaga
-200 ctttaaagcttcctgcctgcatcaccaggaaaacttctttgtaagagtcg
-150 ccacaggattaccagaggttaacctgtttgaagcatcatgtgttaaaaca
-100 acagaaacctgttttcttgtgtggctaactagaaccagagcacaatgttt
-50  ccagttctttgagctccaggaagatagaggacagagttgaaactctgaaa
1    atgcgggcatggactggt.........
dϮƚƌĂŶƐĐƌŝƉƚ
-537              tactttgtgtgccctggcggcgcggctgggtcctccc
-500 gcttagctcgccctctaggacggtctgaggtagtccttcggcccacggct
-450 cagcatcgcgggcatcaggatccccgagtgcgagcgggctgctgttctgg
-400 ctgaggctgtctatggccctggtggcgttttcatccaagatcaagtcctt
-350 tccattattatttattaactgaacagattcagctaataatcttcaagacc
-300 cagatccaagcaataatacacttctctgcagtaccatgtggctttcctca
-250 gcaacctgagtctatgggaaggaagcatgtagagttcatgaagcacaaga
-200 ctttaaagcttcctgcctgcatcaccaggaaaacttctttgtaagagtcg
-150 ccacaggattaccagaggttaacctgtttgaagcatcatgtgttaaaaca
-100 acagaaacctgttttcttgtgtggctaactagaaccagagcacaatgttt
-50  ccagttctttgagctccaggaagatagaggacagagttgaaactctgaaa
1    atgcgggcatggactggt.........
dϯƚƌĂŶƐĐƌŝƉƚ
-222       gtagagttcatgaagcacaaga
-200 ctttaaagcttcctgcctgcatcaccaggaaaacttctttgtaagagtcg
-150 ccacaggattaccagaggttaacctgtttgaagcatcatgtgttaaaaca
-100 acagaaacctgttttcttgtgtggctaactagaaccagagcacaatgttt
-50  ccagttctttgagctccaggaagatagaggacagagttgaaactctgaaa
1    atgcgggcatggactggt.........
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Figure 4 RLM-RACE analysis of fut8 transcripts. (A) The nested
PCR products obtained by RLM-RACE of fut8 transcripts were
analyzed on 1.2% Agarose gel. 1: molecular ladder; 2: negative
control of amplification; 3: PCR negative control; 4: nested PCR
products. (B) Nucleotide sequence of 5’-untranslated regions of T1
[EMBL: FN668936], T2 [EMBL: FN668937] and T3 [EMBL: FN668938]
transcripts. Numbering begins with the initiation codon. The
beginning of the coding sequence is indicated in italics.
Arrowheads indicate the different transcription start sites identified
by RLM-RACE. The exon limits are indicated with back-to-back
arrows.
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Page 10 of 18the promoter sequence, super-shift assay was performed
using anti-KLF15 mAb but no supplementary band was
detected. This result indicates that KLF15 may not
directly interact with the minimal promoter sequence.
Discussion
The rat hybridoma cell line YB2/0 is considered as an
alternative for the large-scale production of low fucose
IgG [9]. The fucose transfer capacity of YB2/0 is much
lower than the other rodent cell lines commonly used
[27]. However, the amount of fucose-negative antibody
produced by YB2/0 significantly decreased with the cul-
ture, due to the elevation of fut8 expression by the YB2/
0 cells [27]. Important variations of the fucose content
are also observed in production culture conditions.
To improve our knowledge of YB2/0 fucosylation
machinery, we have cloned rat fut8 cDNA. Fut8 gene
coding region spans over 140 kb of rat chromosome 6
and splits into nine coding exons with an organization
closely related to that of the human ortholog [33]. The
rat fut8 cDNA contains an ORF of 1725 bp, encoding a
575 amino acids polypeptide, showing 94% and 88%
identity with the human and porcine enzymes, respec-
tively. The amino acids sequence contains the three
specific motifs of a1,6-fucosyltranferase in the catalytic
domain (Figure 2). These motifs are shared by a2-fuco-
syltransferases, a6-fucosyltransferases, and protein-
O-fucosyltransferases (POFUT), indicating that the cor-
responding genes have originated from a common
ancestor by duplication and divergent evolution [34].
Interestingly, we identified 4 nucleotide changes in the
coding sequence of rat fut8 cDNA when compared to
the putative sequence (NM_001002289.1). Two of these
SNP were also found in different EST sequences of the
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Figure 5 Schematic representation of the 5’-untranslated region of fut8 gene and of the three transcript isoforms identified by RLM-
RACE5’. The size of introns is indicated in italics. The size of exons corresponds to the largest identified sequences.
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Figure 6 Quantification of T1 and T2 transcripts expression in YB2/0 and Rat2 cells by duplex Taqman™ QPCR. Results were normalized
to the expression of HPRT mRNA and expressed relative to T1 mRNA expression level in YB2/0. The quantification was performed by the
method described by Livak and Schmittgen [53].
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Page 11 of 18NCBI databases, showing the existence of a silent allelic
polymorphism in rat gene, but without change in the
amino-acid sequence of the polypeptide.
By FISH, we were able to determine the copy number
of fut8 gene in YB2/0, showing a heterogeneous cell
population, 60% of cells having three fut8 copies and
25.5% with 4 or more copies, the mean copy number
being 2.8 ± 1.4 (Figure 3). Hybridoma cell lines such as
YB2/0 are usually tetraploid but are also genetically
instable. Depending on the culture medium, continuous
cultivation induces chromosome rearrangements and
loss of genetic material [35] that can explain fut8 het-
erogeneity. Even if other parameters dependent on the
culture conditions may also influence fut8 expression
during the cultivation, the heterogeneity of fut8 copy
number should also have important consequences in
fucosylation capacity of these cells.
RLM-RACE experiments with capped RNAs allowed
to define for the first time the organization of the
5’-untranslated region of rat fut8 gene and to identify
the different TSS. The rat fut8 gene 5’-untranslated
region contains 4 exons spanning about 90 kb. Three
mRNA isoforms were identified, arising from alternative
splicing and alternative promoter usage, as shown in
Figure 5. The quantification of T1 and T2 transcripts
relative expression was performed by duplex Taqman™
QPCR, showing that T2 transcript was 1.6-fold higher
expressed than the T1. This pattern of expression was
similar in both YB2/0 and Rat2 cell lines. Several TSS
were identified for each transcript, which is a common
attribute for TATA-less promoter [36]. Data concerning
fut8 5’-untranslated region and transcripts expression
are rather limited. It has been shown that in the human
SK-OV-3 ovarian cancer cells, FUT8 expression is con-
trolled by the 5’-flanking region upstream exon 1. How-
ever, other 5’-untranslated sequences were found in
ESTs, suggesting the presence of additional exons
upstream exon 1, and that the transcription of the gene
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Figure 7 Luciferase assays after transfections in Rat2 cells of different plasmid constructs for T1 transcription analysis. (A) Location on
the genomic sequence of the restriction sites used to generate the different deletions of the intronic region between exons E-2 and E-3.
Numbering begins with the initiation codon. (B) On the left, a schematic representation of the different constructs inserted in pGL3b upstream
of the luciferase gene. The gray boxes represent the different deletions of the 1 kbp intronic region between exons E-2 and E-3. The black box
indicates the 5’-end of E-2. Luc indicates the Firefly luciferase coding sequence and the lines indicate the missing sequences. On the right: the
results of luciferase assays. Transfection efficiencies were normalized with the co-transfected plasmid expressing Renilla luciferase and luciferase
activities are expressed compared to pGL3b activity. The data are means +/- S.D. of n > = 3 experiments.
Teylaert et al. BMC Biotechnology 2011, 11:1
http://www.biomedcentral.com/1472-6750/11/1
Page 12 of 18would be regulated by multiple promoters [37]. Two
additional 5’-untranslated exons were identified
upstream human FUT8 exon 1, which are expressed
during embryogenesis as three groups of transcripts,
suggesting an expression of FUT8 regulated by three dif-
ferent promoters [33]. From these data, it appears that
rat and human FUT8 genes have a quite similar organi-
zation and pattern of expression, with at least three dif-
ferent transcripts encoding the same polypeptide.
The alternative first exons E-2 and E-3 are located
about 90 kbp from the first coding exon E1 and separated
b ya1k b pi n t r o n i cs e q u e n c e .T h e1k b pr a tg e n o m i c
sequences upstream exons E-2 and E-3 were cloned in
the pGL3b upstream the luciferase gene to determine the
minimal promoter regions controlling the transcription
of T1 and T2. These plasmids and 5’-o r3 ’-deleted con-
structions were transfected into YB2/0 and Rat2 cells for
luciferase assays. However, the ratio of luminescence
intensity for these different constructions compared to
the control pGL3b was too low to allow determining the
promoter activity in YB2/0. Nevertheless, we were able to
delimitate the minimal promoter regions controlling the
expression of both transcripts in Rat2 cells. We could
show that the T1 transcript is controlled by a minimal
promoter region within the sequence -892/-451 from
ATG with two negative regulation regions within the
-451/-411 and -1438/-1205 sequences. The binding of
Rat2 cells nuclear proteins to the P1 minimal promoter
region was confirmed by EMSA analysis. We also showed
the existence of a minimal promoter region within the
sequence -720/-537 upstream the ATG for transcript T2
and a strong positive regulation region in the exon E-3.
Few are known about the promoters of fut8 in other spe-
cies. Only one study has shown that in human ovarian
cancer cells SK-OV-3, luciferase reporter assay indicated
that the 1 kbp 5’-flanking region of exon E1 conferred
the promoter activity. This region contains a TATA-box,
but not a CCAAT motif, and potential binding sites for
some transcription factors, such as bHLH, cMyb and
GATA-1 [37].
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Figure 8 Luciferase assays after transfections in Rat2 cells of different plasmid constructs for T2 transcription analysis. (A) Location on
the genomic sequence of the restriction sites used to generate the different deletions of the intronic region upstream exon E-3. Numbering
begins with the initiation codon. (B) On the left, a schematic representation of the different constructs inserted in pGL3b upstream of the
luciferase gene. The gray boxes represent the different deletions of the intronic region upstream exon E-3. The black box indicates the exon E-3.
Luc indicates the Firefly luciferase coding sequence and the lines indicate the missing sequences. On the right: the results of luciferase assays.
Transfection efficiencies were normalized with the co-transfected plasmid expressing Renilla luciferase and luciferase activities are expressed
compared to pGL3b activity. The data are means +/- S.D. of n > = 3 experiments.
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Page 13 of 18Bioinformatics analysis of the promoter regions did
not reveal any canonical TATA or CAAT boxes, but
several putative binding sites for general transcription
factors. Absence of TATA or CAAT boxes is a common
feature of glycosyltransferase genes [38]. It is also in
agreement with the presence of several TSS for the
three transcripts, which is usual for such promoter
regions. We also identified in both minimal promoter
sequences several binding sites for transcription factors
with repressor activity, which could be interesting
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Figure 9 In silico analysis of the minimal promoter regions of T1 and T2 transcripts. (A) The 439 bp sequence [EMBL: FN668939] upstream
the TSS (arrowheads) of the shortest T1 transcript were analyzed with Matinspector 2.2 software. Potential transcription factor binding sites are
underlined with black lanes, below the sequence when the binding site is on the -strand and above when the binding site is on the + strand.
Nucleotides are numbered with the nucleotide +1 as the first TSS. (B) The 183 bp sequence [EMBL: FN668940] defined as the minimal promoter
region upstream the T2 transcript was analyzed in the same way.
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Figure 10 Effect of KLF15 over-expression on P1 minimal promoter activity. (A) Detection of KLF15 transcription factor in transiently
transfected Rat2 cells. 48 hours after transfection of Rat2 cells with 25 to 500 ng/mL of pcDNA-hKLF15 or empty (mock) expression vector,
nuclear (N) and cytoplasm (Cyt) proteins were extracted and 20 μg of total protein of each fraction were separated by SDS-PAGE. After transfer
on nitrocellulose membrane, KLF15 was detected by chemiluminescence using anti-KLF15 antibody and horseradish peroxidase conjugated anti-
goat IgG. Actin expression was used as a loading control. (B) Effect of KLF15 overexpression on fut8 P1 minimal promoter activity. Rat2 cells
were co-transfected with 1 μg/mL of pGL3(-892/-451) vector containing the minimal promoter P1 sequence and 0 to 500 ng/mL of pcDNA-
hKLF15 expression vector. 48 hours after transfection, firefly luciferase activity was measured and normalized by Renilla luciferase activity, as
internal control. Histograms show a mean change in relative luciferase expression compared with control transfections, using the same
concentration of empty vector (mock). ** P < 0.0005 (Student test). (C) EMSA analysis of nuclear proteins binding to (-892/-451) P1 promoter
sequence. Lane 1, biotin 5’end-labeled (-892/-451) P1 promoter DNA probe; lane 2, labeled P1 promoter incubated with Rat2 cells nuclear
proteins; lane 3, labeled P1 promoter incubated with Rat2 cells nuclear proteins in the presence of 200-fold molar excess of unlabelled
sequence; lane 4, P1 promoter sequence incubated with nuclear proteins after pre-incubation with anti-KLF15 mAb. Back arrowhead indicates
the electrophoretic mobility of biotin 5’end-labeled (-892/-451) P1 promoter DNA probe and open arrowhead the shift band obtained after
incubation with Rat2 cells nuclear proteins.
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Page 15 of 18targets to regulate fut8 in YB2/0. MZF1 (Myeloid Zinc
Finger 1), PAX5 (Paired Box 5), KLF15 (Krüppel-like
Factor 15), IRF3 (Interferon Regulatory Factor 3) and
PRDM1 (Positive Regulatory Domain containing 1) con-
sensus sequences have been identified in P1 promoter.
MZF1 is known to regulate transcription of genes
involved in cell growth, differentiation and apoptosis of
myeloid cells. It is described as a repressor in non-hema-
topoietic cells and activator in hematopoietic cells [39].
PAX5 is known to down-regulate genes implicated in
myeloid or T-lymphocyte differentiation in pro- B lym-
phocytes [40]. Interestingly, it has been shown that fut8
is up-regulated in PAX5-/- cells [40]. KLF15 has been
demonstrated as a repressor of several important genes
such the adrenomodullin gene in adipocytes [41] or the
rhodopsin and the IRBP (Interphotoreceptor Retinoid
Binding Protein) genes [42]. IRF3 is described as a
repressor of RXRa, which is a key partner for number of
nuclear receptors [43]. PRDM1 (alias Blimp1 or Prd1-
Bf1) is known to repress several critical genes in B lym-
phocytes such as c-Myc [44]. HELT (Hey like transcrip-
tional repressor), CDP (CCAAT displacement protein),
MEL1 (MDS1/EVI1-like gene 1), Nkx3.1 (androgen-regu-
lated homeobox protein), IKRS (Ikaros) and the zinc-fin-
ger transcription factor Gfi-1 were also identified in
minimal promoter P2. HELT was shown to act as a tran-
scriptional repressor in the neuronal development [45].
CDP is known to interact with regulatory element from a
large number of genes involved in differentiation, cell
growth and development. It is acting as a repressor by
either a direct repressing effect when stably bound to the
promoter, or by competing with activator factors for the
occupancy of their binding sites [46]. MEL1 is described
to have an essential function in the proliferation and
maintenance of hematopoietic stem cells [47]. MEL1 is
also known as a transcription repressor factor in the reg-
ulation of calreticulin expression, acting as a competitor
with GATA6 factor [48]. Nkx3.1 is a homeodomain tran-
scription factor, described as a transcriptional inhibitor
of estrogen receptor activity, acting as a putative repres-
sor in hormone-driven tumors [49]. IKRS factors are zinc
finger DNA binding proteins. Six isoforms of IKAROS
are described that often act as repressors. They seem to
have a regulation role in the lymphocyte ontogeny [50].
Gfi-1 is described as a transcriptional repressor in lym-
phoid cell but its function can change with the cell con-
text in hematopoietic development [51].
These transcriptional repressors can potentially bind
to the fut8 minimal promoter regions and, in a first
approach to control fut8 expression, the identified puta-
tive repressors of T1 transcript were co-transfected in
Rat2 cells with reporter vector pGL3(-892/-451) con-
taining the minimal promoter P1 sequence. No repres-
sor activity was observed with MZF1, PAX5, IRF3 or
PRDM1. In particular, we were not able to confirm the
repressor activity of PAX5, as previously demonstrated
in Pax5-/- cells [40]. However, KLF15 expression
induced a 50% decrease of luciferase activity, whatever
the concentration of vector. Western blot analysis of
transfected cell lysates using anti-KLF15 mAb revealed
two bands around 55 kDa. Whereas the theoretical
molecular weight of KLF15 is about 45 kDa, this is in
agreement with the apparent molecular weight of KLF15
protein previously observed in SDS-PAGE [32]. The
8 kDa difference between the two bands could be also
explained by a post-translational modification such as
SUMOylation, as it has been demonstrated for KLF5,
another transcription factor of Krüppel Like Family [52].
Western blot showed that KLF15 is constitutively
expressed in Rat2 cells, mainly in the cytosolic fraction,
and increased in both nucleus and cytoplasm fractions
with the concentration of transfected KLF15 expression
vector in a dose-dependent manner. At the lowest con-
centration of vector, KLF15 is mainly over-expressed in
the nucleus fraction. This is enough to observe a maxi-
mal repressor effect. This result indicates that a low
expression of KLF15 in the nucleus results in a repres-
sion of the P1 minimal promoter activity.
Conclusion
The rat hybridoma cell line YB2/0 is potentially an alter-
native for the large-scale production of low fucose IgG
because of lower fucose transfer capacity compared to
the other rodent cell lines commonly used. However,
nothing was known about the rat a1,6-fucosyltransfer-
ase. Our results shed light on the fut8 gene organization
and expression. Even if many other parameters such as
GDP-Fuc concentration and transport or cell culture
conditions can influence the fucosylation capacity of the
cells, the heterogeneity of fut8 copy number in YB2/0
could explain at least in part the variation of fucose con-
tent in IgG producing cell populations and impedes effi-
cient gene knockdown strategy. Alternatively, the
presence of potential repressor binding sequences in the
minimal promoter regions of fut8 could offer possible
alternatives to control the fucosylation of IgG produced
in these cells.
Additional material
Additional file 1: Effect of transcription factors over-expression on
fut8 P1 minimal promoter activity. Bioinformatics analysis identified
consensus binding sites for PRDM1, IRF3, PAX5, MZF1 and KLF15 putative
repressors in the T1 transcript minimal promoter sequence. Human
coding sequence of PRDM1, IRF3 and MZF1 were cloned into the
pcDNA3.1 expression vector using the Gateway
®® conversion system
(Invitrogen, Carlsbad, CA, USA). The pcDNA3.1 vector containing the
human KLF15 sequence was kindly provided by Dr. Otteson (College of
Optometry, University of Houston, TX, USA) and the pcDNA3.1 vector
containing the human sequence of PAX5 was provided by Dr. Broccardo
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Page 16 of 18(Centre de Physiopathologie INSERM U563, Toulouse, France). Rat2 cells
were co-transfected with 1 μg/mL of pGL3(-892/-451) vector containing
the minimal promoter P1 sequence and 0 to 750 ng/mL of PRDM1 (A),
IRF3 (B), PAX5 (C), MZF1 (D) or KLF15 (E) expression vector. 48 hours after
transfection, firefly luciferase activity was measured and normalized by
Renilla luciferase activity, as internal control. Histograms show a mean
change in relative luciferase expression compared with control
transfections, using the same concentration of empty vector (mock).
* P < 0.01, ** P < 0.0005 (Student test).
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